JP2022535410A5 - - Google Patents
Info
- Publication number
- JP2022535410A5 JP2022535410A5 JP2021571870A JP2021571870A JP2022535410A5 JP 2022535410 A5 JP2022535410 A5 JP 2022535410A5 JP 2021571870 A JP2021571870 A JP 2021571870A JP 2021571870 A JP2021571870 A JP 2021571870A JP 2022535410 A5 JP2022535410 A5 JP 2022535410A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- taci
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856998P | 2019-06-04 | 2019-06-04 | |
| US62/856,998 | 2019-06-04 | ||
| US201962907930P | 2019-09-30 | 2019-09-30 | |
| US62/907,930 | 2019-09-30 | ||
| US202063012735P | 2020-04-20 | 2020-04-20 | |
| US63/012,735 | 2020-04-20 | ||
| PCT/US2020/036108 WO2020247618A1 (en) | 2019-06-04 | 2020-06-04 | Antibodies and chimeric antigen receptors that target taci |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535410A JP2022535410A (ja) | 2022-08-08 |
| JP2022535410A5 true JP2022535410A5 (https=) | 2023-06-13 |
| JP7584453B2 JP7584453B2 (ja) | 2024-11-15 |
Family
ID=73652958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571870A Active JP7584453B2 (ja) | 2019-06-04 | 2020-06-04 | Ｔａｃｉを標的とする抗体及びキメラ抗原受容体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12595303B2 (https=) |
| EP (1) | EP3980454A4 (https=) |
| JP (1) | JP7584453B2 (https=) |
| CN (1) | CN114206919B (https=) |
| AU (1) | AU2020287626A1 (https=) |
| CA (1) | CA3139057A1 (https=) |
| WO (1) | WO2020247618A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020247618A1 (en) | 2019-06-04 | 2020-12-10 | The General Hospital Corporation | Antibodies and chimeric antigen receptors that target taci |
| US20240245772A1 (en) * | 2021-05-19 | 2024-07-25 | Celledit Llc | Bi-specific chimeric antigen receptors and genetically engineered immune cells expressing such |
| WO2023178073A2 (en) * | 2022-03-15 | 2023-09-21 | Celledit Llc | Use of antigen presenting cells to enhance car-t cell therapy |
| WO2024056009A1 (zh) * | 2022-09-14 | 2024-03-21 | 荣昌生物制药(烟台)股份有限公司 | 一种taci抗体及其用途 |
| WO2024102067A1 (en) * | 2022-11-08 | 2024-05-16 | Agency For Science, Technology And Research | Antigen binding protein specific for transmembrane activator and caml interactor (taci) |
| CN117288933A (zh) * | 2023-09-21 | 2023-12-26 | 桂林医学院附属医院 | 检测car-t细胞杀伤力的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7083950B2 (en) * | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
| WO2002066516A2 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| WO2004011611A2 (en) | 2002-07-25 | 2004-02-05 | Genentech, Inc. | Taci antibodies and uses thereof |
| WO2004074511A1 (en) * | 2003-02-21 | 2004-09-02 | Garvan Institute Of Medical Research | Diagnosis and treatment of baff-mediated autoimmune diseases and cancer |
| EP2130552B1 (en) * | 2007-02-27 | 2016-06-15 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising anti-grp78 antibody as active ingredient |
| CA2939411A1 (en) * | 2014-02-27 | 2015-09-03 | Ucl Business Plc | Ligand |
| WO2018028647A1 (en) | 2016-08-10 | 2018-02-15 | Legend Biotech Usa Inc. | Chimeric antigen receptors targeting bcma and methods of use thereof |
| EP3340995A4 (en) * | 2015-08-28 | 2019-04-03 | The Trustees Of The University Of Pennsylvania | METHOD AND COMPOSITIONS FOR CELLS FOR EXPRESSING A CHIMERIC INTRA-CELLULAR SIGNAL MOLECULE |
| JP2019535262A (ja) * | 2016-11-11 | 2019-12-12 | オートラス リミテッド | キメラ抗原受容体 |
| CN108490174B (zh) | 2018-04-18 | 2022-06-24 | 上海尚珞生物医药科技有限公司 | 检测car-t细胞的方法及其应用 |
| WO2020247618A1 (en) | 2019-06-04 | 2020-12-10 | The General Hospital Corporation | Antibodies and chimeric antigen receptors that target taci |
-
2020
- 2020-06-04 WO PCT/US2020/036108 patent/WO2020247618A1/en not_active Ceased
- 2020-06-04 JP JP2021571870A patent/JP7584453B2/ja active Active
- 2020-06-04 US US17/616,274 patent/US12595303B2/en active Active
- 2020-06-04 CN CN202080054113.3A patent/CN114206919B/zh active Active
- 2020-06-04 EP EP20818549.6A patent/EP3980454A4/en active Pending
- 2020-06-04 CA CA3139057A patent/CA3139057A1/en active Pending
- 2020-06-04 AU AU2020287626A patent/AU2020287626A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022535410A5 (https=) | ||
| TWI883026B (zh) | 抗ｄｌｌ３嵌合抗原受體及其用途 | |
| JP7809680B2 (ja) | 癌処置のための多重特異性結合タンパク質 | |
| JP2022512684A5 (https=) | ||
| JP2022504802A5 (https=) | ||
| CA3086653A1 (en) | Tumor necrosis factor (tnf) receptor superfamily (tnfrsf) receptor-activating antibody fusion proteins with fcyr-independent agonistic activity (tnfrsf receptor-activating antibody fusion proteins with fcyr-independ ent agonistic activity; traaffiaa) | |
| JP2022542543A5 (https=) | ||
| JP2017527275A5 (https=) | ||
| US20240209106A1 (en) | Anti-cd137 antibodies and methods of use | |
| US20240190983A1 (en) | Novel TNFR2 Binding Molecules | |
| JP2024054284A (ja) | ガンの処置のための結合分子 | |
| JP2023511898A5 (https=) | ||
| US20240400705A1 (en) | Composition of recombinant antigen binding molecules and method of making and using thereof | |
| WO2024193669A1 (zh) | 抗tnfr2/抗pd-1或ctla-4双特异性抗体及其应用 | |
| JP2025528835A5 (https=) | ||
| CN119894930A (zh) | 一种双特异性抗体及其应用 | |
| JP2024514101A5 (https=) | ||
| CN117164719A (zh) | 靶向SIRPα和PD-L1的双特异性抗体或其抗原结合片段及应用 | |
| WO2024094151A1 (en) | Multi-specific antibody and medical use thereof | |
| RU2023128561A (ru) | Gucy2c-связывающий полипептид и его применение | |
| JP2025539145A (ja) | 抗ｃｄ１３７抗体及びその使用方法 | |
| WO2023067138A1 (en) | Uses of gamma delta t cell activating antibodies | |
| JP2025087939A (ja) | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体の使用 | |
| HK40065826A (zh) | 抗dll3嵌合抗原受体及其用途 | |
| Zhu et al. | Dual-Targeting Bispecific Antibodies as New Therapeutic Modalities for Cancer |